July 30, 2026Journal of the American College of Cardiology123 citations
View Full PaperPrescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
Key Points
- This research aims to analyze how prescriber patterns for SGLT2i medications change following FDA labeling expansions.
- Analyzed data from FDA labeling changes relevant to SGLT2i medications.
- Evaluated prescriber behavior trends before and after label expansions.
- Utilized statistical analysis to assess impacts on medication prescriptions.
- Prescriber rates for SGLT2i increased by 30% post-label expansion.
- Higher adherence to prescribing guidelines was noted (p<0.05).
- Differential adoption rates observed among specialties, with endocrinologists leading.
Abstract
Sodium glucose cotransporter-2 inhibitors (SGLT2i) are glucose-lowering therapies with distinct cardiometabolic health benefits. Empagliflozin was shown to reduce risk of cardiovascular death among high-risk patients with type 2 diabetes mellitus (1)1, which led to the U.S. Food and Drug